Day Two | Thursday, September 25, 2025

8:00 am Morning Coffee & Registration

8:50 am Chair’s Opening Remarks

Navigating Current Regulatory Challenges to Unlock Global Market Growth

9:00 am Using Platform Strategy Approach to Accelerate Device Submission

  • Lisa Ray Executive Director; Program Management and Operations Device Development, Eli Lilly & Co.

Synopsis

  • Sharing acceleration levers utilized to accelerate device submission
  • Outlining details related to leveraging an existing device platform strategy while balancing other portfolio priorities
  • Explaining key learnings toward resources required to implement platform approach replication of this strategy across other device programs

9:30 am Decoding EDDO Guidance: Accelerating Market Readiness for Injectable Devices

  • Abhishek Telang Senior Director - Device Quality & Regulatory, Merck & Co

Synopsis

  • Facilitating cross-industry dialogue to accelerate interpretation and adoption
  • Linking device functionality to regulatory expectations to avoid submission delays
  • Contextual assessment of EDDO applicability to prevent over-interpreting guidance

10:00 am Roundtable Discussion: Navigating the Effects of U.S. Policy Shifts in Pharma Supply Chains

Synopsis

  • Understanding tariff impacts to inform resilient sourcing and budgeting strategies
  • Discussing long-term strategic options for pharma companies and CMOs to adapt procurement and manufacturing models in response to the evolving U.S. trade policy
  • Identifying supply chain vulnerabilities, including regulatory and quality risks tied to international component and service providers

10:30 am Morning Break & Networking

Overcoming Usability & Alignment Gaps to Optimize Patient-Centric Device Design

11:30 am Usability Considerations for Large Volume Subcutaneous (LVSC) Oncology Medication

  • Alison Bisch Associate Principal Human Factors Engineer, AstraZeneca

Synopsis

  • Outlining ergonomic challenges and the impact of LVSC on nurses’ workload in oncology clinics
  • Discussing key insights from usability studies on nurses’ capability and acceptability for administering LVSC medication
  • Translating usability study results into actionable recommendations for device development

12:00 pm Embedding Patient Centric Design Considerations Into Risk Management & Device Selection to Improve Product Safety

Synopsis

  • Reviewing aspects of the patient population that should be considered when identifying product risks and designing products to control those risks
  • Selecting and tailoring delivery devices based on patient characteristics and patient experience
  • Exploring the challenges of device selection in a world of platforms

12:30 pm Lunch Break & Networking

Aligning Strategy, Functions, & Partners to Accelerate Injectable Device Development

1:30 pm Accelerating Timelines from Device Selection to IND Submission

  • Krishna Patel Senior Director, Quality Engineering, Immunovant, Inc.
  • Scott Stiffler Device Engineering & Global Technology Leader, Immunovant, Inc.

Synopsis

  • Driving early device planning with clinical and commercial expectations
  • Effective cross-functional alignment on device development strategies (DV, shipping studies, E&L, HF)
  • Onboarding manufacturing CMOs for combination product design transfer (Supplier audits, design transfer planning, assembly line qualification, and risk based control strategy)

2:00 pm Innovative Device Strategies for Brain-Targeted Drug Delivery to Overcome Barriers and Enable Collaborative Development

Synopsis

  • Overcoming challenges in brain drug delivery: Develop approaches to bypass the blood-brain barrier and reduce risks from invasive methods for safer, more effective treatments
  • Innovating delivery methods: Explore novel devices and alternative delivery routes to enhance how drugs are delivered to the brain
  • Collaborating for better solutions Integrate advancements in device design, modelling, drug formulation and related innovations to develop more effective therapies for brain disorders

2:30 pm Afternoon Break & Networking

Developing Strategic Partnerships, Cost Efficiency & Digital Acceleration for Scalable Success

3:30 pm Strategies for Selecting Fully Integrated Partners to Streamline Injectable Device Supply Chains

  • Edward Hatton Director, Quality Assurance - External Manufacturing, Amneal Pharmaceuticals, Inc.

Synopsis

  • Discussing how to evaluate true end-to-end CDMO capabilities to reduce handoffs and misaligned timelines
  • Proactively identifying geographic and single-source material risks early in project planning
  • Partnering for scalability to mitigate disruption as project volumes increase or shift
  • Assessing real-world pitfalls of fragmented outsourcing and practical solutions to avoid them

4:00 pm Roundtable Discussion: Managing Costs & Reimbursement in the Development of High-Value Injectable Devices

Synopsis

  • Navigating milestone payments and risk management for investment success
  • Evaluating the supply chain to reduce unnecessary expenses including overspill
  • Exploring pricing and reimbursement strategies early in development to ensure market access and commercial viability

4:30 pm Leveraging AI & Digital Strategies to Drive Efficiency in Device Development

Synopsis

  • Exploring how AI and digital tools can streamline and enhance the device development process
  • Discussing the role of advanced technologies in improving efficiency and decision-making across development stages

5:00 pm Chair’s Closing Remarks

End of the Conference